検索
Telix Pharmaceuticals Ltd
TLXウォッチリストに追加
11.950USD
+0.640+5.66%
終値 09-22 16:00（ET）
0.00時価総額
0.00直近12ヶ月PER
前場取引 05:27 (ET)11.570USD-0.380-3.18%
前場取引 05:27 (ET)Telix Pharmaceuticals Ltdについて 企業名
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Telix Pharmaceuticals Ltd プロフィール
企業コードTLX
会社名Telix Pharmaceuticals Ltd
上場日Nov 15, 2017
最高経営責任者「CEO」Ortiz (Raphaeel)
従業員数- -
証券種類Depository Receipt
決算期末- -
本社所在地55 Flemington Road
都市MELBOURNE
証券取引所NASDAQ OMX - NASDAQ BASIC
国Australia
郵便番号3051
電話番号61390933855
ウェブサイトhttps://telixpharma.com/
企業コードTLX
上場日Nov 15, 2017
最高経営責任者「CEO」Ortiz (Raphaeel)
Telix Pharmaceuticals Ltdの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Cade, M.D.
Dr. David Cade, M.D.
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Dr. Darren Patti, Pharm.D.
Dr. Darren Patti, Pharm.D.
Group Chief Operating Officer
Group Chief Operating Officer
--
--
Ms. Marie McDonald
Ms. Marie McDonald
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. David Gill
Mr. David Gill
Non-Executive Chair of the Board
Non-Executive Chair of the Board
--
--
Ms. Shomalin Naidoo
Ms. Shomalin Naidoo
Interim Company Secretary
Interim Company Secretary
--
--
Dr. Maria Rivas, M.D.
Dr. Maria Rivas, M.D.
Additional Non-Executive Director
Additional Non-Executive Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Cade, M.D.
Dr. David Cade, M.D.
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Dr. Darren Patti, Pharm.D.
Dr. Darren Patti, Pharm.D.
Group Chief Operating Officer
Group Chief Operating Officer
--
--
よくある質問
Telix Pharmaceuticals Ltdの上位5名の株主は誰ですか？
Telix Pharmaceuticals Ltdの上位5名の株主は以下のとおりです。Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Telix Pharmaceuticals Ltd（TLX）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Telix Pharmaceuticals Ltdの株式を保有している機関は61社あり、保有株式の総市場価値は約1.47Mで、全体の0.43%を占めています。2025Q4と比較して、機関の持ち株は326197.00増加しています。